Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Xeris Biopharma Holdings (XERS) Leases (2022 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Leases for 4 consecutive years, with $22.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Leases fell 2.37% year-over-year to $22.1 million, compared with a TTM value of $22.1 million through Dec 2025, down 2.37%, and an annual FY2025 reading of $22.1 million, down 2.37% over the prior year.
  • Leases was $22.1 million for Q4 2025 at Xeris Biopharma Holdings, down from $22.3 million in the prior quarter.
  • Across five years, Leases topped out at $23.6 million in Q2 2023 and bottomed at $3.9 million in Q1 2023.
  • Average Leases over 4 years is $19.9 million, with a median of $22.6 million recorded in 2024.
  • Peak annual rise in Leases hit 492.56% in 2024, while the deepest fall reached 3.25% in 2024.
  • Year by year, Leases stood at $4.0 million in 2022, then skyrocketed by 481.26% to $23.2 million in 2023, then decreased by 2.39% to $22.6 million in 2024, then decreased by 2.37% to $22.1 million in 2025.
  • Business Quant data shows Leases for XERS at $22.1 million in Q4 2025, $22.3 million in Q3 2025, and $22.4 million in Q2 2025.